Das pharmakologische Profil von Sildenafil zeigt neben der PDE5-Inhibition auch eine geringe Aktivität an der PDE6 in der Retina. Dies erklärt visuelle Nebenwirkungen wie Farbsehstörungen, die gelegentlich auftreten. Die orale Bioverfügbarkeit beträgt etwa 40 %, mit einer hohen Bindung an Plasmaproteine. Das Verteilungsvolumen ist groß, sodass die Substanz rasch in verschiedene Gewebe gelangt. Die Metabolisierung erfolgt hepatisch und produziert einen aktiven Metaboliten, der die pharmakologische Wirkung ergänzt. Nebenwirkungen sind dosisabhängig und umfassen Kopfschmerzen, Hautrötung und Dyspepsie. Bei Vergleichen innerhalb der Wirkstoffklasse wird viagra original regelmäßig als Beispiel für eine Substanz mit schneller, aber kurzzeitiger Wirkung aufgeführt.

Sanwashoyaku.co.jp

Standard Commodity Classification No. of Japan This product is easy to take, fine granules made from the extract of “ogonto”listed in“SHOKANRON”. Storage・Caution Keep a container tightly closed in a dry area away from Date of listing in the NHI reimbursement price October 1986 Expiration date Use before the expiration date indicated on the label or the outer package. CONTRAINDICATIONS ( Ogonto is contraindicated in (1) When this product is used, the patient’s“SHO”(con- stitution/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is obse- [1-3: These diseases or symptoms may be aggravated.] rved, continuous treatment should be avoided. (2) Since this product contains Glycyrrhiza, careful atte- ntion should be paid to the serum potassium level,bl- 7.5g/day of SANWA Ogonto extract fine granules contains ood pressure,etc., and if any abnormality is observed, 4.0g of a dried extract of the following mixed crude drugs. (3) When this product is coadministered with other Ka- mpo-preparations(Japanese traditional herbal medi- cines),etc.,attention should be paid to the duplicatio- SHO：The term“SHO”refers to a particular pathological status of a patient evaluated by the Kampo diagnosis,a- nd is patterned according to the patient’s constitution,s- ymptoms, etc. Kampo-preparations(Japanese tradition- al herbal medicines) should be used after confirmation that it is suitable for the identified“SHO”of the patient. Precautions for coadministration ( Ogonto should be ad- Ogonto is fine granules, yellow-brown color, it has charac- ministered with care when coadministered with the fol- teristic smell, and it tastes sweet and bitter. Ogonto is indicated for the relief of intestinal catarrh, dy- ur as a result of hy- potassium excreti- The usual adult dose is 7.5g/day orally in 3 divided doses before or between meals. The dosage may be adjusted ac- cording to the patient’s age and symptoms. This product has not been investigated(drug use investiga- tions, etc.)to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known. (1) Clinically significant adverse reactions 1) Pseudoaldosteronism: Pseudoaldosteronism such as hypokalemia, increased blood pressure, retention of sodium/body fluid, edema, increased body weight,etc. may occur. The patient should be carefully monitore- d (measurement of serum potassium level, etc.), and if any abnormality is observed, administration shoul d be discontinued and appropriate measures such as administration of potassium preparations should be 2) Myopathy: Myopathy may occur as a result of hypo- kalemia. The patient should be carefully monitored, and if any abnormality such as weakness, convulsio- n/paralysis of limbs, etc. are observed, administrati- on should be discontinued and appropriate measure- s such as administration of potassium preparations Because elderly patients often have reduced physiological function, careful supervision and measures such as reduc- 5. Use during Pregnancy, Delivery or Lactation The safety of this product in pregnant women has not be- en established. Therefore, the product should be used in pregnant women, women who may possibly be pregnant only if the expected therapeutic benefits outweigh the p- ossible risks associated with treatment. 6. Pediatric Use The safety of this product in children has not been estab- lished. [Insufficient clinical data.] PACKAGING Bottles of 500g 2.5g×300 packets Manufactured and Distributed by: 6-1, Hiraide-Kogyo-Danchi, Utsunomiya-city, Tochigi 321-0905, Japan

Source: http://www.sanwashoyaku.co.jp/products/upload_docs/EPIPDougontou1.pdf